Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair
Abstract
Neuroinflammation in Parkinson's disease [PD] is a process that occurs alongside the loss of dopaminergic neurons, and is associated with alterations to many cell types, most notably microglia. This review examines the key evidence contributing to our understanding of the role of inflammation-mediated degeneration of the dopaminergic (DA) nigrostriatal pathway in PD. It will consider the potential role inflammation plays in tissue repair within the brain, inflammation linked gene products that are associated with sporadic Parkinsonian phenotypes (alpha-synuclein, Parkin and Nurr 1), and developing anti-inflammatory drug treatments in PD. With growing evidence supporting the key role of neuroinflammation in PD pathogenesis, new molecular targets are being found that could potentially prevent or delay nigrostriatal DA neuron loss. Hence, this creates the opportunity for disease modifying treatment, to currently what is an incurable disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Mitochondrial malfunction leads to reduced energy metabolism and induces neuroinflammation via NO and ROS production, ultimately entailing neurodegeneration.
“It has been suggested that mitochondrial malfunction leads to reduced energy metabolism and induces neuroinflammation via NO and ROS production, which ultimately entails neurodegeneration (Vivekanantham et al., 2015).”
From The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma. (2017) · cites this paper as Vivekanantham et al., 2015
Cites
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · see citing works
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · see citing works
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290 · see citing works
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,274 · see citing works
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · see citing works
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172 · see citing works
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046 · cited 1× · see citing works
“Mutant mice lacking iNOS genes were more susceptible to toxic effects of MPTP than controls [72].”
BackgroundLang, A. E., Gill, S., Patel, N., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G. R., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 987 · see citing works
Nalls, M., Plagnol, V., Hernandez, D., Sharma, M., Sheerin, U., Saad, M., Simón-Sánchez, J., Schulte, C., Lesage, S., Sveinbjörnsdóttir, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62345-8 · Cited by 986 · see citing works
Oxidative stress and the pathogenesis of Parkinson's disease
Jenner, P., & Olanow, C. W. (1996) · Neurology · doi:10.1212/wnl.47.6_suppl_3.161s · Cited by 971 · see citing works
Saijo, K., Winner, B., Carson, C. T., Collier, J. G., Boyer, L., Rosenfeld, M. G., Gage, F. H., & Glass, C. K. (2009) · Cell · doi:10.1016/j.cell.2009.01.038 · Cited by 859 · see citing works
Antioxidants, Oxidative Stress, and Degenerative Neurological Disorders
Floyd, R. A. (1999) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-140.x · Cited by 824 · see citing works
Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J. S., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J. E., Pugh, E., et al. (2010) · Nature Genetics · doi:10.1038/ng.642 · Cited by 779 · see citing works
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733 · see citing works
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · see citing works
Wu, D., Teismann, P., Tieu, K., Vila, M., Jackson-Lewis, V. R., Ischiropoulos, H., & Przedborski, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937239100 · Cited by 634 · see citing works
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 630 · see citing works
Inflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 628 · see citing works
Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A. M., & Adorini, L. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.4.1945 · Cited by 617 · see citing works
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 610 · see citing works
Tansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 580 · see citing works
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 557 · see citing works
Reinhardt, P., Schmid, B., Burbulla, L. F., Schöndorf, D. C., Wagner, L., Glatza, M., Höing, S., Hargus, G., Heck, S. A., Dhingra, A., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.008 · Cited by 500 · see citing works
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., Giaveri, G., Arosio, P., Santambrogio, P., Fariello, R. G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403495101 · Cited by 495 · see citing works
Mutations in NR4A2 associated with familial Parkinson disease
Le, W., Xu, P., Jankovic, J. J., Jiang, H. F., Appel, S. H., Smith, R. G., & Vassilatis, D. K. (2002) · Nature Genetics · doi:10.1038/ng1066 · Cited by 488 · see citing works
Synuclein activates microglia in a model of Parkinson's disease
Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · cited 1× · see citing works
“Overexpression of the wild type SYN in culture causes increased microglial expression of pro-inflammatory molecules as determined by mRNA analysis [24].”
BackgroundNonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 470 · see citing works
Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease
Nichols, W. C., Pankratz, N., Hernandez, D., Paisán-Ruíz, C., Jain, S., Halter, C. A., Michaels, V. E., Reed, T., Rudolph, A., Shults, C. W., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17828-3 · Cited by 457 · see citing works
The pathogenesis of cell death in Parkinson's disease
Jenner, P. G., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 449 · see citing works
Ghosh, A., Roy, A., Liu, X., Kordower, J. H., Mufson, E. J., Hartley, D. M., Ghosh, S., Mosley, R. L., Gendelman, H. E., & Pahan, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704908104 · Cited by 438 · see citing works
Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration
Gao, H., Kotzbauer, P. T., Uryu, K., Leight, S., Trojanowski, J. Q., & Lee, V. M. ‐. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0143-07.2008 · Cited by 435 · see citing works
Microglial phenotype: is the commitment reversible?
Schwartz, M., Butovsky, O., Brück, W., & Hanisch, U.-K. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2005.12.005 · Cited by 434 · see citing works
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease
Reynolds, A. D., Banerjee, R., Liu, J., Gendelman, H. E., & Mosley, R. L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0507296 · Cited by 422 · see citing works
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041584.x · Cited by 393 · see citing works
Reynolds, A. D., Stone, D. K., Hutter, J. A. L., Benner, E., Mosley, R., & Gendelman, H. E. (2010) · Journal of Immunology · doi:10.4049/jimmunol.0901852 · Cited by 391 · see citing works
Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation
Teismann, P., & Schulz, J. B. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0944-0 · Cited by 363 · see citing works
Liu, Z., Lee, J., Krummey, S. M., Lü, W., Cai, H., & Lenardo, M. J. (2011) · Nature Immunology · doi:10.1038/ni.2113 · Cited by 361 · see citing works
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., & Hong, J.-S. (2011) · Environmental Health Perspectives · doi:10.1289/ehp.1003013 · Cited by 355 · see citing works
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 355 · see citing works
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336 · see citing works
Hakimi, M., Selvanantham, T., Swinton, E., Padmore, R., Tong, Y., Kabbach, G., Venderová, K., Girardin, S. E., Bulman, D. E., Scherzer, C. R., et al. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0653-2 · Cited by 284 · see citing works
Interleukin-1 mediates Alzheimer and Lewy body pathologies
Griffin, W. S. T., Liu, L., Li, Y., Mrak, R. E., & Barger, S. W. (2006) · Journal of Neuroinflammation · doi:10.1186/1742-2094-3-5 · Cited by 262 · see citing works
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration
Purisai, M. G., McCormack, A. L., Cumine, S., Li, J., Isla, M. Z., & Monte, D. A. D. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.008 · Cited by 255 · see citing works
Inflammation and Adaptive Immunity in Parkinson's DiseasePreprint
Mosley, R. L., Hutter-Saunders, J. A. L., Stone, D. K., & Gendelman, H. E. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 246 · see citing works
Regulating Factors for Microglial Activation.
Nakamura, Y. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.945 · Cited by 241 · see citing works
Mitochondrial dysfunction: A potential link between neuroinflammation and neurodegeneration?
Witte, M. E., Geurts, J. J. G., de Vries, H. E., van der Valk, P., & van Horssen, J. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.05.014 · Cited by 236 · see citing works
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236 · see citing works
Faucheux, B. A., Martin, M., Beaumont, C., Hauw, J., Agid, Y., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01923.x · Cited by 229 · see citing works
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227 · see citing works
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218 · see citing works
The pathogenesis of cell death in Parkinson's disease – 2007
Olanow, C. W. (2007) · Movement Disorders · doi:10.1002/mds.21675 · Cited by 212 · see citing works
Zecca, L., Wilms, H., Geick, S., Claasen, J.-H., Brandenburg, L.-O., Holzknecht, C., Panizza, M. L., Zucca, F. A., Deuschl, G., Sievers, J., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0361-7 · Cited by 205 · see citing works
Sánchez‐Pernaute, R., Ferree, A. W., Cooper, O., Yu, M., Brownell, A., & Ole Isacson, A. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-6 · Cited by 205 · see citing works
Batchelor, P. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1185 · Cited by 199 · see citing works
Nitrated α-Synuclein-Induced Alterations in Microglial Immunity Are Regulated by CD4+ T Cell Subsets
Reynolds, A. D., Stone, D. K., Mosley, R. L., & Gendelman, H. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803982 · Cited by 197 · see citing works
CNS Infiltration of Peripheral Immune Cells: D-Day for Neurodegenerative Disease?
Rezai-Zadeh, K. P., Gate, D., & Town, T. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9166-2 · Cited by 194 · see citing works
COX‐2 and Neurodegeneration in Parkinson's Disease
Teismann, P., Vila, M., Choi, D., Tieu, K., Wu, D.-C., Jackson-Lewis, V. R., & Przedborski, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07482.x · Cited by 178 · see citing works
Genome-wide association study confirms extant PD risk loci among the Dutch
Simón‐Sánchez, J., van Hilten, J. J., van de Warrenburg, B. P. C., Post, B., Berendse, H. W., Arepalli, S., Hernandez, D. G., de Bie, R. M. A., Velseboer, D. C., Scheffer, H., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.254 · Cited by 178 · see citing works
Neuroinflammation in Parkinson’s Disease
Lee, J., Tran, T. A. T., & Tansey, M. G. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9176-0 · Cited by 174 · see citing works
NSAID Use and the Risk of Parkinsonʼs Disease
Samii, A., Etminan, M., Wiens, M. O., & Jafari, S. (2009) · Drugs & Aging · doi:10.2165/11316780-000000000-00000 · Cited by 161 · see citing works
Identification of blood serum micro‐RNAs associated with idiopathic and LRRK2 Parkinson's disease
Botta‐Orfila, T., Morató, X., Compta, Y., Lozano, J. J., Falgàs, N., Valldeoriola, F., Pont‐Sunyer, C., Vilas, D., Mengual, L., Fernández, M., et al. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23377 · Cited by 143 · see citing works
α-Synuclein Expression Modulates Microglial Activation Phenotype
Austin, S. A., Floden, A. M., Murphy, E. J., & Combs, C. K. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1799-06.2006 · Cited by 142 · see citing works
Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease
Hernán, M. Á., Logroscino, G., & Rodríguez, L. A. G. (2006) · Neurology · doi:10.1212/01.wnl.0000204446.82823.28 · Cited by 137 · see citing works
Increase in Peripheral CD4 Bright+ CD8 Dull+ T Cells in Parkinson Disease
Hisanaga, K., 浅黄美沙, Itoyama, Y., & Iwasaki, Y. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1580 · Cited by 131 · see citing works
Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies.
Tanner, C. M. (2003) · PubMed · Cited by 130 · see citing works
Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease
Stone, D. K., Reynolds, A. D., Mosley, R. L., & Gendelman, H. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2460 · Cited by 130 · see citing works
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 130 · see citing works
LRRK2 Mutations in Spanish Patients With Parkinson Disease
Gaig, C., Ezquerra, M., Martı́, M. J., Muñoz, E., Valldeoriola, F., & TOLOSA, E. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.377 · Cited by 123 · see citing works
Nagatsu, T., & Sawada, M. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9061-9 · Cited by 122 · see citing works
Tanaka, S., Ishii, A., Ohtaki, H., Shioda, S., Yoshida, T., & Numazawa, S. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-143 · Cited by 118 · see citing works
Lipopolysaccharide and Tumor Necrosis Factor Regulate Parkin Expression via Nuclear Factor-Kappa B
Tran, T. A. T., Nguyen, A. D., Chang, J., Goldberg, M. S., Lee, J., & Tansey, M. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023660 · Cited by 112 · see citing works
Bruno, R., Sabater, L., Sospedra, M., Ferrer-Francesch, X., Escudero, D., Martínez-Cáceres, E. M., & Pujol‐Borrell, R. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(2002010)32:10 · Cited by 102 · see citing works
Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases.
Shoham, S., & Youdim, M. B. H. (2000) · PubMed · Cited by 101 · see citing works
Ossola, B., Schendzielorz, N., Chen, S., Bird, G. S. J., Tuominen, R. K., Männistö, P. T., & Hong, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.030 · Cited by 97 · see citing works
Driver, J. A., Logroscino, G., Lu, L., Gaziano, J. M., & Kurth, T. (2011) · BMJ · doi:10.1136/bmj.d198 · Cited by 81 · see citing works
Human Interleukin-10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease
Johnston, L. C., Su, X., Maguire‐Zeiss, K. A., Horovitz, K., Ankoudinova, I., Guschin, D. Y., Hadaczek, P., Federoff, H. J., Bankiewicz, K. S., & Forsayeth, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.113 · Cited by 80 · see citing works
NSAID use and risk of Parkinson disease: a population‐based case‐control study
Becker, C., Jick, S. S., & Meier, C. R. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03399.x · Cited by 75 · see citing works
Familial Parkinson's disease. Alpha-synuclein and parkin.
Mizuno, Y., Hattori, N., Kitada, T., Matsumine, H., Mori, H., Shimura, H., Kubo, S., Kobayashi, H., Asakawa, S., Minoshima, S., et al. (2001) · PubMed · Cited by 72 · see citing works
Association of the human leucocyte antigen region with susceptibility to Parkinson's disease
Saiki, M., Baker, A., Williams‐Gray, C. H., Foltynie, T., Goodman, R. S., Taylor, C. J., Compston, D. A. S., Barker, R., Sawcer, S. J., & Goris, A. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.162883 · Cited by 68 · see citing works
Shamoto‐Nagai, M., Maruyama, W., Yi, H. L., Akao, Y., Tribl, F., Gerlach, M., Osawa, T., Riederer, P. F., & Naoi, M. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0410-5 · Cited by 67 · see citing works
Thakur, P. S., & Nehru, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.006 · Cited by 65 · see citing works
Iravani, M. M., Sadeghian, M., Leung, C. C. M., Jenner, P. G., & Rose, S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.01.022 · Cited by 51 · see citing works
PERIPHERAL-TYPE BENZODIAZEPINE BINDING IN ALZHEIMER DISEASE
McGeer, E. G., Singh, E. A., & McGeer, P. L. (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802040-00001 · Cited by 49 · see citing works
Dopamine‐dependent neurotoxicity of lipopolysaccharide in substantia nigra
de Pablos, R. M., Herrera, A. J., Villarán, R. F., Cano, J., & Machado, A. (2004) · The FASEB Journal · doi:10.1096/fj.04-2153fje · Cited by 45 · see citing works
Human leukocyte antigen variation and Parkinson’s disease
Puschmann, A., Verbeeck, C., Heckman, M. G., Soto‐Ortolaza, A. I., Lynch, T., Jasińska‐Myga, B., Opala, G., Krygowska‐Wajs, A., Barcikowska, M., Uitti, R. J., et al. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.03.008 · Cited by 41 · see citing works
Tasaki, Y., Yamamoto, J., Omura, T., Sakaguchi, T., Kimura, N., Ohtaki, K., Ono, T., Suno, M., Asari, M., Ohkubo, T., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.045 · Cited by 25 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466 · see citing works
Giacobbe, J., Benoiton, B., Zunszain, P., Pariante, C. M., & Borsini, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00122 · Cited by 159 · see citing works
Zhang, Q.-S., Heng, Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.002 · Cited by 156 · see citing works
Nuzum, N. D., Loughman, A., Szymlek-Gay, E. A., Hendy, A., Teo, W.-P., & Macpherson, H. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.003 · Cited by 103 · see citing works
Palasz, E., Niewiadomski, W., Gasiorowska, A., Wysocka, A., Stepniewska, A., & Niewiadomska, G. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01143 · Cited by 95 · see citing works
O’Donovan, S. M., Crowley, E. K., Brown, J. R. ‐., O’Sullivan, O., O’Leary, O. F., Timmons, S., Nolan, Y. M., Clarke, D. J., Hyland, N. P., Joyce, S. A., et al. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13726 · Cited by 86 · see citing works
Palasz, E., Niewiadomski, W., Gasiorowska, A., Mietelska-Porowska, A., & Niewiadomska, G. (2019) · Neural Plasticity · doi:10.1155/2019/8215017 · Cited by 39 · see citing works
Su, Y., Liu, Y., He, D., Hu, G., Wang, H., Ye, B., He, Y., Gao, X., & Liu, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108694 · Cited by 26 · see citing works
- Authors
- Vivekanantham, S., Shah, S., Dewji, R., Dewji, A., Khatri, C., & Ologunde, R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Vivekanantham, Sayinthen
- Venue
- International Journal of Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2015-05-22
- Volume
- 125
- Issue
- 10
- Pages
- 717-725
- ISSN
- 0020-7454 (ISSN-L)
- 1543-5245
- OpenAlex
- W2148731774
- Cited by
- 171
- References
- 86
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 11 · 2023: 14 · 2022: 13 · 2021: 22 · 2020: 26 · 2019: 22 · 2018: 18 · 2017: 15 · 2016: 9 · 2015: 4
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- neuroinflammation, Parkinson's disease, neurodegeneration, microglia, dopaminergic neurons, nigrostriatal pathway, tissue repair, alpha-synuclein, Parkin, Nurr1, anti-inflammatory agents, disease-modifying therapy
- MeSH terms
- Animals, Anti-Inflammatory Agents, Brain, Humans, Inflammation, Nerve Degeneration, Parkinson Disease, Microglia, Genetic Predisposition to Disease, Dopaminergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
